(1H-Benzoimidazol-5-yl)-(5-bromo-2-chloro-pyrimidin-4-yl)-amine | 852357-08-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (1H-Benzoimidazol-5-yl)-(5-bromo-2-chloro-pyrimidin-4-yl)-amine
• 英文别名: (5-bromo-2-chloro-pyrimidin-4-yl)-(1H-benzimidazol-5-yl)-amine；N-(5-bromo-2-chloropyrimidin-4-yl)-3H-benzimidazol-5-amine
• CAS: 852357-08-5
• 化学式: C₁₁H₇BrClN₅
• 分子量: 324.567
• InChiKey: UEKUDSYNSPIWAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (1H-Benzoimidazol-5-yl)-(5-bromo-2-chloro-pyrimidin-4-yl)-amine 、 4-(3-吡啶基氧基)苯胺 在 盐酸 作用下， 以 正丁醇 为溶剂， 反应 12.0h， 生成 4-N-(3H-benzimidazol-5-yl)-5-bromo-2-N-(4-pyridin-3-yloxyphenyl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors

  摘要：

  A series of aminobenzimidazole-substituted pyrimidines were synthesized and evaluated for biochemical activity against CDK1. A high-speed parallel synthesis approach enabled the identification of a potent lead series having improved potency in the CDK1 assay (IC50 < 10 nM). Cell cycle analysis showed that the compounds induced a G2/M block. Docking studies were carried out with a CDK1 homology model, and provide a rationale for the observed activities. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.076
• 作为产物：
  描述：

  5-溴-2,4-二氯嘧啶 、 5-氨基苯并咪唑 在 sodium carbonate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以93%的产率得到(1H-Benzoimidazol-5-yl)-(5-bromo-2-chloro-pyrimidin-4-yl)-amine
  参考文献：
  名称：

  Carbamoylsulphoximides as protein kinase inhibitors

  摘要：

  这项发明涉及一般公式1的羰基硫氧亚胺类蛋白激酶抑制剂。

  公开号：

  US20080167330A1

文献信息

• Carbamoylsulphoximides as protein kinase inhibitors
  申请人：Luecking Ulrich

  公开号：US20080167330A1

  公开（公告）日：2008-07-10

  The invention relates to carbamoylsulphoximides as protein kinase inhibitors of the general formula 1.

  这项发明涉及一般公式1的羰基硫氧亚胺类蛋白激酶抑制剂。
• SULFOXIMIDE ALS PROTEINKINASEINHIBITOREN
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2059511A1

  公开（公告）日：2009-05-20
• [DE] SULFOXIMIDE ALS PROTEINKINASEINHIBITOREN<br/>[EN] SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS<br/>[FR] SULFOXIMIDES COMME INHIBITEURS DE PROTÉINES KINASES
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2008025556A1

  公开（公告）日：2008-03-06

  [EN] The invention relates to carbamoylsulphoximides as protein kinase inhibitors of the general formula (I).
  [FR] L'invention concerne des carbamoylsulfoximides de formule générale (I) utilisables comme inhibiteurs de protéines kinases.
  [DE] Die Erfindung betrifft Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren der allgemeinen Formel (I).
• Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors
  作者：Sharad Verma、Dhanapalan Nagarathnam、Jianxing Shao、Lei Zhang、Jin Zhao、Yamin Wang、Tindy Li、Eric Mull、Istvan Enyedy、Chunguang Wang、Qingming Zhu、Martha Altieri、Jerold Jordan、Thu-Thi-Anh Dang、Sanjeeva Reddy

  DOI：10.1016/j.bmcl.2005.02.076

  日期：2005.4

  A series of aminobenzimidazole-substituted pyrimidines were synthesized and evaluated for biochemical activity against CDK1. A high-speed parallel synthesis approach enabled the identification of a potent lead series having improved potency in the CDK1 assay (IC50 < 10 nM). Cell cycle analysis showed that the compounds induced a G2/M block. Docking studies were carried out with a CDK1 homology model, and provide a rationale for the observed activities. (c) 2005 Elsevier Ltd. All rights reserved.